<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9304532</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2286</journal-id>
<journal-id journal-id-type="nlm-ta">Stem Cells</journal-id>
<journal-id journal-id-type="iso-abbrev">Stem Cells</journal-id>
<journal-title-group>
<journal-title>Stem cells (Dayton, Ohio)</journal-title>
</journal-title-group>
<issn pub-type="ppub">1066-5099</issn>
<issn pub-type="epub">1549-4918</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26840228</article-id>
<article-id pub-id-type="pmc">4803616</article-id>
<article-id pub-id-type="doi">10.1002/stem.2295</article-id>
<article-id pub-id-type="manuscript">NIHMS750701</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Progress and challenges in using human stem cells for biological and therapeutics discovery: neuropsychiatric disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Panchision</surname>
<given-names>David M.</given-names>
</name>
<aff id="A1">Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, Bethesda, MD, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1">Correspondence: David M. Panchision, Ph.D., Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, 6001 Executive Boulevard, MSC 9641, Bethesda, MD 20892-9641. Phone: 301-443-5288; Fax: 301-451-5615; <email>panchisiond@mail.nih.gov</email></corresp>
<fn fn-type="conflict" id="FN3">
<p><bold>Disclosure:</bold> The author indicates no potential conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>34</volume>
<issue>3</issue>
<fpage>523</fpage>
<lpage>536</lpage>
<!--elocation-id from pubmed: 10.1002/stem.2295-->
<abstract>
<p id="P1">In facing the daunting challenge of using human embryonic and induced pluripotent stem cells (hESCs, hiPSCs) to study complex neural circuit disorders such as schizophrenia (SCZ), mood and anxiety disorders and autism spectrum disorders (ASDs), a 2012 National Institute of Mental Health workshop produced a set of recommendations to advance basic research and engage industry in cell-based studies of neuropsychiatric disorders. This review describes progress in meeting these recommendations, including the development of novel tools, strides in recapitulating relevant cell and tissue types, insights into the genetic basis of these disorders that permit integration of risk-associated gene regulatory networks with cell/circuit phenotypes, and promising findings of patient-control differences using cell-based assays. However, numerous challenges are still being addressed, requiring further technological development, approaches to resolve disease heterogeneity and collaborative structures for investigators of different disciplines. Additionally, since data obtained so far is on small sample sizes, replication in larger sample sets is needed. A number of individual success stories point to a path forward in developing assays to translate discovery science to therapeutics development.</p>
</abstract>
<kwd-group>
<kwd>induced pluripotent stem cells</kwd>
<kwd>induced neuronal cells</kwd>
<kwd>schizophrenia</kwd>
<kwd>bipolar disorder</kwd>
<kwd>autism spectrum disorders</kwd>
<kwd>genetics</kwd>
<kwd>drug discovery</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>